{"id":"mipomersen","rwe":[{"pmid":"41394159","year":"2025","title":"Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41349489","year":"2026","title":"Heat stress enhances VLDL secretion in chicken ovarian follicles to potentiate its impact on follicular cell survival and maturation.","finding":"","journal":"Poultry science","studyType":"Clinical Study"},{"pmid":"41151185","year":"2025","title":"Functional MTTP and apoB for VLDL secretion in chicken ovaries support small follicle development under heat stress.","finding":"","journal":"Journal of thermal biology","studyType":"Clinical Study"},{"pmid":"40104114","year":"2025","title":"Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models.","finding":"","journal":"Molecular therapy. Nucleic acids","studyType":"Clinical Study"},{"pmid":"40073639","year":"2025","title":"Ovarian expression of functional MTTP and apoB for VLDL assembly and secretion in chickens.","finding":"","journal":"Poultry science","studyType":"Clinical Study"}],"tags":[{"label":"Antisense Oligonucleotide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C10AX11","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Familial hypercholesterolemia - homozygous","category":"indication"},{"label":"Kastle Theraps Llc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"},{"label":"Molecular Probes","category":"pharmacology"},{"label":"Oligodeoxyribonucleotides, Antisense","category":"pharmacology"},{"label":"Oligonucleotides, Antisense","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":89.269,"date":"","count":29,"signal":"Injection site pain","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=89)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Kastle Theraps Llc","patents":[{"applNo":"N203568","source":"FDA Orange Book","status":"Active","expires":"Jan 29, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7511131","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MIPOMERSEN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:30:49.056291+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:30:49.055781+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:30:55.340569+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIPOMERSEN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:30:56.150012+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2219536/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:56.721995+00:00"}},"allNames":"kynamro","offLabel":[],"synonyms":["mipomersen","mipomersen sodium","kynamro","ISIS 301012","ISIS-301012"],"timeline":[{"date":"2013-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GENZYME CORP to Kastle Theraps Llc"},{"date":"2027-01-29","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7511131 expires"}],"aiSummary":"Kynamro (Mipomersen) is an antisense oligonucleotide developed by Genzyme Corp and currently owned by Kastle Therapies LLC. It is a small molecule modality approved by the FDA in 2013 for the treatment of familial hypercholesterolemia in homozygous patients. Kynamro works by targeting a specific gene to reduce the production of apolipoprotein B, a key component of low-density lipoprotein (LDL) cholesterol. The drug is patented and has no generic manufacturers. Key safety considerations include liver toxicity and elevations in liver enzymes.","approvals":[{"date":"2013-01-29","orphan":true,"company":"GENZYME CORP","regulator":"FDA"}],"brandName":"Kynamro","ecosystem":[{"indication":"Familial hypercholesterolemia - homozygous","otherDrugs":[{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"evolocumab","slug":"evolocumab","company":"Repatha"},{"name":"ezetimibe","slug":"ezetimibe","company":"Msd Intl Gmbh"},{"name":"lomitapide","slug":"lomitapide","company":"Aegerion"}],"globalPrevalence":390000000}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Antisense Oligonucleotide","explanation":"","oneSentence":"","technicalDetail":"Kynamro is an antisense oligonucleotide that binds to the mRNA sequence of the apolipoprotein B gene, leading to the degradation of the mRNA and subsequent reduction in apolipoprotein B production. This results in decreased levels of LDL cholesterol and increased levels of high-density lipoprotein (HDL) cholesterol."},"commercial":{"launchDate":"2013","_launchSource":"DrugCentral (FDA 2013-01-29, GENZYME CORP)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4747","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIPOMERSEN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIPOMERSEN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:48:09.277511","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:58.600067+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dextrothyroxine","drugSlug":"dextrothyroxine","fdaApproval":"1967-04-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"probucol","drugSlug":"probucol","fdaApproval":"1977-02-01","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ezetimibe","drugSlug":"ezetimibe","fdaApproval":"2002-10-25","patentExpiry":"Apr 30, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lomitapide","drugSlug":"lomitapide","fdaApproval":"2012-12-21","patentExpiry":"Aug 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evolocumab","drugSlug":"evolocumab","fdaApproval":"2015-08-28","relationship":"same-class"},{"drugName":"alirocumab","drugSlug":"alirocumab","fdaApproval":"2015-07-24","relationship":"same-class"},{"drugName":"bempedoic acid","drugSlug":"bempedoic-acid","fdaApproval":"2020-02-21","patentExpiry":"Mar 14, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inclisiran","drugSlug":"inclisiran","fdaApproval":"2021-12-22","patentExpiry":"May 10, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evinacumab","drugSlug":"evinacumab","fdaApproval":"2021-02-11","relationship":"same-class"}],"genericName":"mipomersen","indications":{"approved":[{"name":"Familial hypercholesterolemia - homozygous","source":"DrugCentral","snomedId":238078005,"regulator":"FDA","usPrevalence":86000000,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO Global Health Estimates, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Kastle Theraps Llc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"dextrothyroxine","brandName":"dextrothyroxine","genericName":"dextrothyroxine","approvalYear":"1967","relationship":"same-class"},{"drugId":"probucol","brandName":"probucol","genericName":"probucol","approvalYear":"1977","relationship":"same-class"},{"drugId":"ezetimibe","brandName":"ezetimibe","genericName":"ezetimibe","approvalYear":"2002","relationship":"same-class"},{"drugId":"lomitapide","brandName":"lomitapide","genericName":"lomitapide","approvalYear":"2012","relationship":"same-class"},{"drugId":"evolocumab","brandName":"evolocumab","genericName":"evolocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"alirocumab","brandName":"alirocumab","genericName":"alirocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"bempedoic-acid","brandName":"bempedoic acid","genericName":"bempedoic acid","approvalYear":"2020","relationship":"same-class"},{"drugId":"inclisiran","brandName":"inclisiran","genericName":"inclisiran","approvalYear":"2021","relationship":"same-class"},{"drugId":"evinacumab","brandName":"evinacumab","genericName":"evinacumab","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01475825","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2011-12","conditions":["Hypercholesterolemia","Heterozygous Familial"],"enrollment":309,"completionDate":"2015-12-29"},{"nctId":"NCT00362180","phase":"PHASE2","title":"Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2006-07","conditions":["Lipid Metabolism, Inborn Errors","Hyperlipidemias","Metabolic Diseases","Hypolipoproteinemia","Hypolipoproteinemias","Hypobetalipoproteinemias","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Congenital Abnormalities","Metabolic Disorder","Hypercholesterolemia","Dyslipidemias","Lipid Metabolism Disorders"],"enrollment":38,"completionDate":"2010-09"},{"nctId":"NCT00477594","phase":"PHASE2","title":"Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2007-05","conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"enrollment":21,"completionDate":"2011-07"},{"nctId":"NCT00607373","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2007-07","conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"enrollment":51,"completionDate":"2009-03"},{"nctId":"NCT00694109","phase":"PHASE3","title":"An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2008-04","conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"enrollment":144,"completionDate":"2014-09"},{"nctId":"NCT00706849","phase":"PHASE3","title":"Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2008-07","conditions":["Heterozygous Familial Hypercholesterolemia","Coronary Artery Disease"],"enrollment":124,"completionDate":"2010-05"},{"nctId":"NCT00794664","phase":"PHASE3","title":"Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2009-01","conditions":["Hypercholesterolemia","Coronary Heart Disease"],"enrollment":58,"completionDate":"2010-10"},{"nctId":"NCT00770146","phase":"PHASE3","title":"Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2008-11","conditions":["Hypercholesterolemia","Coronary Heart Disease"],"enrollment":158,"completionDate":"2010-10"},{"nctId":"NCT00707746","phase":"PHASE2","title":"Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2008-10","conditions":["Metabolic Diseases","Hyperlipidemias","Metabolic Disorder","Hypercholesterolemia","Dyslipidemias","Lipid Metabolism Disorders"],"enrollment":34,"completionDate":"2011-01"},{"nctId":"NCT01414881","phase":"PHASE1","title":"Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2011-09","conditions":["Healthy Volunteer"],"enrollment":20,"completionDate":"2012-11"},{"nctId":"NCT01299298","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2011-01","conditions":["Healthy Volunteer"],"enrollment":20,"completionDate":"2011-04"},{"nctId":"NCT01061814","phase":"PHASE1","title":"A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2010-01","conditions":["Healthy Volunteer"],"enrollment":84,"completionDate":"2010-06"},{"nctId":"NCT00281008","phase":"PHASE2","title":"Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2006-02","conditions":["Hypercholesterolemia, Familial"],"enrollment":44,"completionDate":"2007-12"},{"nctId":"NCT01090661","phase":"PHASE1","title":"A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2010-03","conditions":["Healthy"],"enrollment":60,"completionDate":"2010-05"},{"nctId":"NCT00280995","phase":"PHASE2","title":"Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2006-01","conditions":["Hypercholesterolemia, Familial"],"enrollment":12,"completionDate":"2007-08"},{"nctId":"NCT00231569","phase":"PHASE2","title":"Dose-escalating Safety Study in Subjects on Stable Statin Therapy","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2005-09","conditions":["Hypercholesterolemia"],"enrollment":74,"completionDate":"2007-12"},{"nctId":"NCT00216463","phase":"PHASE2","title":"Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2005-08","conditions":["Hypercholesterolemia"],"enrollment":50,"completionDate":"2007-08"},{"nctId":"NCT01133366","phase":"PHASE1","title":"A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2010-05","conditions":["Healthy"],"enrollment":18,"completionDate":"2010-07"},{"nctId":"NCT01598948","phase":"PHASE3","title":"Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-08","conditions":["Atherosclerosis","LDL-hypercholesterolemia"],"enrollment":17,"completionDate":"2015-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Kynamro"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000186782","MMSL":"198505","NDDF":"014906","UNII":"9GJ8S4GU0M","VUID":"4032221","VANDF":"4032221","INN_ID":"8946","RXNORM":"1367838","UMLSCUI":"C2604635","chemblId":"CHEMBL2219536","ChEMBL_ID":"CHEMBL2219536","KEGG_DRUG":"D08946","DRUGBANK_ID":"DB05528","PUBCHEM_CID":"44564107","SNOMEDCT_US":"716221002","IUPHAR_LIGAND_ID":"7364","SECONDARY_CAS_RN":"1000120-98-8","MESH_SUPPLEMENTAL_RECORD_UI":"C524142"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2013-","companyName":"Genzyme Corp","relationship":"Original Developer"},{"period":"present","companyName":"Kastle Theraps Llc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"17.6 hours","clearance":"0.67 mL/min/kg","fractionUnbound":"0.05%","volumeOfDistribution":"0.1 L/kg"},"publicationCount":231,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AX11","allCodes":["C10AX11"]},"biosimilarFilings":[],"originalDeveloper":"Genzyme Corp","recentPublications":[{"date":"2025","pmid":"41394159","title":"Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.","journal":"Frontiers in pharmacology"},{"date":"2026 Jan","pmid":"41349489","title":"Heat stress enhances VLDL secretion in chicken ovarian follicles to potentiate its impact on follicular cell survival and maturation.","journal":"Poultry science"},{"date":"2025 Oct","pmid":"41151185","title":"Functional MTTP and apoB for VLDL secretion in chicken ovaries support small follicle development under heat stress.","journal":"Journal of thermal biology"},{"date":"2025 Mar 11","pmid":"40104114","title":"Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models.","journal":"Molecular therapy. Nucleic acids"},{"date":"2025 May","pmid":"40073639","title":"Ovarian expression of functional MTTP and apoB for VLDL assembly and secretion in chickens.","journal":"Poultry science"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Kastle Theraps Llc","companyId":"kastle-theraps-llc","modality":"Oligonucleotide","firstApprovalDate":"2013","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"GENZYME CORP","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:58.600067+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}